Lugo-Peña Julián, Medina Héctor M, Umaña Juan P, Valderrama-Achury María Daniela, Torres Adriana
Department of Clinical Cardiology, Fundación Cardioinfantil-Instituto de Cardiología, Calle 163A # 13B-60, Bogotá 110311, Colombia.
Cardiac Imaging, Texas Heart Institute, 6770 Bertner Avenue, Houston, TX 77030, USA.
Eur Heart J Case Rep. 2025 Jun 5;9(7):ytaf279. doi: 10.1093/ehjcr/ytaf279. eCollection 2025 Jul.
Primary cardiac lymphoma (PCL) involves the heart almost exclusively although it can extend to surrounding structures including the pericardium. Most PCLs in adults are of B-cell origin and their signs and symptoms are generally non-specific and depend on their location and size. In general, cancer patients usually have a slim chance of receiving heart transplantation (OHT), although it's not an absolute contraindication depending on the decision of the multidisciplinary team and the experience of each institution.
A 48-year-old man, with an ultimate diagnosis of primary cardiac follicular B-cell lymphoma presented to our hospital mimicking hypertrophic cardiomyopathy. He initially presented with worsening heart failure and ventricular tachycardia storm (VT-S) that required urgent cardiac OHT. The final pathological analysis of the explanted heart revealed the presence of a PCL without extra-cardiac extension. In addition to initial immunosuppression with mycophenolate mophethyl, corticosteroids, and tacrolimus, he was switched to Everolimus and dose reduction of Tacrolimus. Rituximab + Bendamustine was initiated to reduce the risk of cardiotoxicity and myelotoxicity associated to R-CHOP. The follow-up body PET-CT, -thoracic echocardiogram, cardiac magnetic resonance imagings and biopsies were normal. During a regular follow-up heart biopsy procedure to ascertain rejection, the patient developed torrential tricuspid regurgitation and required surgical valve replacement.
After 5.5 years of follow-up, the patient remains asymptomatic, with normal graft function, in NYHA FC I, and without oncological relapses despite receiving a modified chemotherapy regimen. Selected patients with a PCL can be managed with OHT and a modified chemotherapy regimen. They could also be followed up using a non-invasive approach to monitor rejection.
原发性心脏淋巴瘤(PCL)几乎仅累及心脏,尽管它可扩展至包括心包在内的周围结构。大多数成人PCL起源于B细胞,其体征和症状通常不具有特异性,取决于其位置和大小。一般来说,癌症患者接受心脏移植(OHT)的机会通常很小,尽管根据多学科团队的决定和各机构的经验,这并非绝对禁忌证。
一名48岁男性,最终诊断为原发性心脏滤泡性B细胞淋巴瘤,以肥厚型心肌病的表现就诊于我院。他最初表现为心力衰竭加重和室性心动过速风暴(VT-S),需要紧急进行心脏OHT。切除心脏的最终病理分析显示存在无心脏外扩展的PCL。除了最初使用霉酚酸酯、皮质类固醇和他克莫司进行免疫抑制外,他改用了依维莫司并减少了他克莫司的剂量。开始使用利妥昔单抗+苯达莫司汀以降低与R-CHOP相关的心脏毒性和骨髓毒性风险。后续的全身PET-CT、胸部超声心动图、心脏磁共振成像和活检均正常。在一次定期的心脏活检以确定排斥反应的过程中,患者出现了严重的三尖瓣反流,需要进行手术瓣膜置换。
经过5.5年的随访,患者仍无症状,移植心脏功能正常,纽约心脏协会(NYHA)心功能分级为I级,尽管接受了改良化疗方案,但无肿瘤复发。部分PCL患者可通过OHT和改良化疗方案进行治疗。也可采用非侵入性方法对他们进行随访以监测排斥反应。